1 – 15 of 21
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
(
- Contribution to journal › Article
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
- 2022
-
Mark
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
(
- Contribution to journal › Article
-
Mark
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
(
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
- 2021
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
- 2020
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
(
- Contribution to journal › Article